The United Kingdom is currently facing a significant crisis due to a widespread shortage of aspirin, an essential medication that plays a crucial role in preventing strokes and heart attacks among at-risk individuals. In response to this alarming situation, the Government has taken the step of including aspirin on its export ban list, a move intended to ensure that there are enough supplies available for patients in the UK while addressing the manufacturing delays that have been identified as a key factor contributing to the shortages.
Both the National Pharmacy Association (NPA), which represents around 6,000 pharmacies, and the Independent Pharmacies Association, comprising over 5,000 members, have reported serious challenges in obtaining the drug. This has led to pharmacists across the nation being forced to ration their existing supplies carefully, prioritizing those patients who are suffering from severe heart conditions or who require urgent prescriptions.
The low-dose 75mg aspirin is particularly important for long-term management of heart health due to its ability to prevent blood clots, thereby reducing the risk of heart attacks and strokes. Physicians often prescribe this medication for individuals who have experienced a heart attack, stroke, transient ischemic attack, angina, peripheral arterial disease (PAD), or have undergone certain types of surgery.
A recent quick survey conducted by the NPA, which included responses from 540 pharmacies across the UK, revealed that an astounding 86% reported being unable to provide aspirin to their patients within the last week. While the shortage is particularly acute for the 75mg doses, all variations of the medication are experiencing availability issues.
Many pharmacies have also ceased offering aspirin for over-the-counter sales, further exacerbating the problem. The NPA has noted that the price of aspirin has surged significantly in the past two months due to these shortages. For example, a packet of 75mg dispersible tablets has increased from just 18 pence last year to an astonishing £3.90 this month. Given that the NHS only reimburses pharmacies £2.18 per packet, this means that pharmacies face a loss of approximately £1.72 every time they dispense this medication.
Olivier Picard, the chair of the NPA, expressed his concerns regarding the implications of these shortages, stating, "We’re worried about reports of pharmacies struggling to obtain aspirin and what that means for the patients they serve. For those pharmacies that manage to secure stock, costs far exceed what they will receive from the NHS in reimbursement, highlighting a fundamentally broken pharmacy contract that desperately needs reform from the Government."
Dr. Leyla Hannbeck, chief executive of the Independent Pharmacies Association, echoed these sentiments, noting, "It’s deeply concerning to witness shortages of critical medications like aspirin and blood pressure treatments in our pharmacies. These low stock levels are partly due to manufacturing delays, but also because pharmacies are unable to order the necessary quantities. The reality is that the NHS sets prices for many medicines so low that manufacturers often choose to supply other countries instead, leaving the UK at the end of the line. When limited supplies do become available, prices skyrocket, making them unaffordable for pharmacies, which then suffer significant financial losses. It’s crucial for the Government to urgently revisit how medicines are reimbursed to pharmacies; otherwise, these shortages will only continue to escalate. Meanwhile, anyone affected by a medicine shortage should consult their local pharmacist, who is a highly trained healthcare professional and can recommend suitable alternatives when available."
The NPA advocates for changes to regulations that restrict pharmacies from providing alternative medications or preparations to what is prescribed. Mr. Picard emphasized, "We have long advocated for pharmacists to be allowed to make substitutions when a medicine is out of stock and it is safe to offer an alternative. The current state of affairs is not only frustrating for patients; it is also hazardous. It is nonsensical to send someone back to their GP for a prescription change when a safe alternative is readily available. This could lead to unnecessary delays in patients receiving crucial medication or, worse, result in them forgoing it entirely, which poses a clear risk to their health."
James Davies, the director of research and insights at Community Pharmacy England, stated that medication shortages "remain a significant concern for both patients and community pharmacies." He added, "As these shortages continue to impact patients and pharmacy teams nationwide, it is imperative that the Government and the NHS take immediate action to stabilize the medicinal market, address supply chain disruptions, and enhance patient access to essential medications."
Fiona Loud, policy director at Kidney Care UK, pointed out that this shortage also affects individuals with chronic kidney disease, who may be prescribed low-dose aspirin to mitigate their risk of strokes and heart attacks.
